Emerging anti-spike monoclonal antibodies against SARS-CoV-2
EE Ordaya, RR Razonable - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies (mAbs) were previously authorized for the
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
RR Razonable - Expert Opinion on Biological Therapy, 2023 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies were highly effective for prophylaxis and early
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …
treatment of mild-to-moderate COVID-19 in high-risk populations. Areas covered This article …
SARS-CoV-2 evolution during prolonged infection in immunocompromised patients
AD Marques, J Graham-Wooten, AS Fitzgerald… - Mbio, 2024 - Am Soc Microbiol
Prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
immunocompromised patients provides an opportunity for viral evolution, potentially leading …
immunocompromised patients provides an opportunity for viral evolution, potentially leading …
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised …
S Huygens, C GeurtsvanKessel… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Immunocompromised patients (ICPs) have an increased risk for a
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …
Treatment-Emergent Cilgavimab Resistance Was Uncommon in Vaccinated Omicron BA. 4/5 Outpatients
CEM Gruber, FG Tucci, M Rueca, V Mazzotta… - Biomolecules, 2023 - mdpi.com
Mutations in the SARS-CoV-2 Spike glycoprotein can affect monoclonal antibody efficacy.
Recent findings report the occurrence of resistant mutations in immunocompromised …
Recent findings report the occurrence of resistant mutations in immunocompromised …
SARS‐CoV‐2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients
Neutralizing antispike monoclonal antibody (mAb) therapies were highly efficacious in
preventing coronavirus disease 2019 (COVID‐19) hospitalization. While severe acute …
preventing coronavirus disease 2019 (COVID‐19) hospitalization. While severe acute …
Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA. 2 and …
R Reindl-Schwaighofer, A Heinzel, L Raab, R Strassl… - …, 2024 - thelancet.com
Background The response to severe acute respiratory syndrome coronavirus type 2 (SARS-
CoV-2) vaccination is severely impaired in patients on maintenance immunosuppression …
CoV-2) vaccination is severely impaired in patients on maintenance immunosuppression …
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective …
S Huygens, C GeurtsvanKessel… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Immunocompromised patients (ICPs) have an increased risk for a
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …
severe and prolonged COVID-19. SARS-CoV-2 monoclonal antibodies (mAbs) were …
Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies
S Feng, GE Reid, NM Clark, A Harrington… - Virology Journal, 2024 - Springer
Background The factors contributing to the accelerated convergent evolution of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) are not fully understood. Unraveling the …
respiratory syndrome coronavirus 2 (SARS-CoV-2) are not fully understood. Unraveling the …
Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal …
J Kim, S Kim, S Park, D Kim, M Kim, K Baek… - Microbes and …, 2024 - Elsevier
SARS-CoV-2 mutations have resulted in the emergence of multiple concerning variants, with
Omicron being the dominant strain presently. Therefore, we developed a monoclonal …
Omicron being the dominant strain presently. Therefore, we developed a monoclonal …